CTOs on the Move

XinVivo

www.xinvivo.com

 
XinVivo – a UNC spin-out founded in 2015 and based off Airport Boulevard in Morrisville. The company specializes in developing and manufacturing 3D imaging systems. Specifically, the company is developing carbine nanotube X-ray source array technology, which it claims increases speed while reducing radiation and costs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.xinvivo.com
  • 507 Airport Boulevard Suite 107
    Morrisville, NC USA 27560
  • Phone: 919.701.4100

Executives

Name Title Contact Details

Funding

XinVivo raised $25.3M on 10/29/2019

Similar Companies

Med-stat Inc

Med-stat Inc is a Sterling Heights, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DXE Medical

DXE Medical is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

03 Innovations

03 Innovations Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

e-PharmPro

e-PharmPro is a Brookhaven, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sight Sciences

Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.